A Revolutionary Platform for Drug Discovery

GigaGen’s platform is a proven first-in-class technology that extends beyond just discovery – it integrates deep repertoire mining with yeast protein expression to deliver millions-diverse, natively-paired scFv libraries that can be screened for clones using fluorescence-activated cell sorting (FACS), and enables affinity maturation of promising therapeutic candidates. Benefits of this approach include:


  • Deeper epitopic diversity

  • Higher binding affinity

  • Improved expressibility

  • Identification of rare and unique antibodies

  • Faster development timelines


Since 2014, we have been using our integrated discovery and engineering platform to extract novel therapeutic candidates from natural immune repertoires. We have partnered with numerous academic institutions and leading biopharma companies to successfully tackle hard-to-solve discovery and development problems that have failed using traditional technologies. We have successfully replicated the antibody diversity of over 50 human donors to create the world’s first recombinant form of intravenous immunoglobulin (IVIG) - a first-in-class polyclonal therapeutic. We have also established an internal pipeline of monoclonal immuno-oncology candidates against 15 targets.


For the first time ever, we can understand immune response to disease with incredible breadth and detail and use this power to create lifesaving therapies.